世界の移行細胞がん治療薬市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Transitional Cell Cancer Therapeutics Market Size, Status and Forecast 2021-2027

• レポートコード：QYR2104Z5717 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、98ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥553,800 (USD3,900)	▷ お問い合わせ
Multi User/Five User	￥830,700 (USD5,850)	▷ お問い合わせ
Enterprise License（同一法人内共有可）	￥1,107,600 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査資料では、移行細胞がん治療薬のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（膀胱腫瘍経尿道切除術、膀胱切除術、尿路変更術）、用途別市場規模（病院、がん研究所、専門クリニック、外来手術センター）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・移行細胞がん治療薬の市場動向 ・企業の競争状況、市場シェア ・移行細胞がん治療薬の種類別市場規模（膀胱腫瘍経尿道切除術、膀胱切除術、尿路変更術） ・移行細胞がん治療薬の用途別市場規模（病院、がん研究所、専門クリニック、外来手術センター） ・移行細胞がん治療薬の北米市場規模2016-2027（アメリカ、カナダ） ・移行細胞がん治療薬のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・移行細胞がん治療薬のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・移行細胞がん治療薬の中南米市場規模2016-2027（メキシコ、ブラジル） ・移行細胞がん治療薬の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（AstraZeneca、Roche、Bristol-Myers Squibb、Pfizer、Exelixis、Eisai、Merck、Eli Lilly、Celgene） ・結論

Transitional cell carcinoma (TCC) occur in the different parts of urinary tract, which include kidney, bladder, or urethra.
Market revenue drivers for the transitional cell cancer therapeutics market include increase in environmental pollution levels coupled with high rates of cigarette smoking.

Market Analysis and Insights: Global Transitional Cell Cancer Therapeutics Market
The global Transitional Cell Cancer Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Transitional Cell Cancer Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Transitional Cell Cancer Therapeutics market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Transitional Cell Cancer Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Transitional Cell Cancer Therapeutics market.

Global Transitional Cell Cancer Therapeutics Scope and Market Size
Transitional Cell Cancer Therapeutics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Transitional Cell Cancer Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Transurethral Resection Of Bladder Tumor
Cystectomy
Urinary Diversion

Segment by Application
Hospital
Cancer Research Institutes
Multispecialty Clinics
Ambulatory Surgical Centers

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
AstraZeneca
Roche
Bristol-Myers Squibb
Pfizer
Exelixis
Eisai
Merck
Eli Lilly
Celgene

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Transitional Cell Cancer Therapeutics Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Transurethral Resection Of Bladder Tumor
1.2.3 Cystectomy
1.2.4 Urinary Diversion
1.3 Market by Application
1.3.1 Global Transitional Cell Cancer Therapeutics Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital
1.3.3 Cancer Research Institutes
1.3.4 Multispecialty Clinics
1.3.5 Ambulatory Surgical Centers
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Transitional Cell Cancer Therapeutics Market Perspective (2016-2027)
2.2 Transitional Cell Cancer Therapeutics Growth Trends by Regions
2.2.1 Transitional Cell Cancer Therapeutics Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Transitional Cell Cancer Therapeutics Historic Market Share by Regions (2016-2021)
2.2.3 Transitional Cell Cancer Therapeutics Forecasted Market Size by Regions (2022-2027)
2.3 Transitional Cell Cancer Therapeutics Industry Dynamic
2.3.1 Transitional Cell Cancer Therapeutics Market Trends
2.3.2 Transitional Cell Cancer Therapeutics Market Drivers
2.3.3 Transitional Cell Cancer Therapeutics Market Challenges
2.3.4 Transitional Cell Cancer Therapeutics Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Transitional Cell Cancer Therapeutics Players by Revenue
3.1.1 Global Top Transitional Cell Cancer Therapeutics Players by Revenue (2016-2021)
3.1.2 Global Transitional Cell Cancer Therapeutics Revenue Market Share by Players (2016-2021)
3.2 Global Transitional Cell Cancer Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Transitional Cell Cancer Therapeutics Revenue
3.4 Global Transitional Cell Cancer Therapeutics Market Concentration Ratio
3.4.1 Global Transitional Cell Cancer Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Transitional Cell Cancer Therapeutics Revenue in 2020
3.5 Transitional Cell Cancer Therapeutics Key Players Head office and Area Served
3.6 Key Players Transitional Cell Cancer Therapeutics Product Solution and Service
3.7 Date of Enter into Transitional Cell Cancer Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Transitional Cell Cancer Therapeutics Breakdown Data by Type
4.1 Global Transitional Cell Cancer Therapeutics Historic Market Size by Type (2016-2021)
4.2 Global Transitional Cell Cancer Therapeutics Forecasted Market Size by Type (2022-2027)

5 Transitional Cell Cancer Therapeutics Breakdown Data by Application
5.1 Global Transitional Cell Cancer Therapeutics Historic Market Size by Application (2016-2021)
5.2 Global Transitional Cell Cancer Therapeutics Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Transitional Cell Cancer Therapeutics Market Size (2016-2027)
6.2 North America Transitional Cell Cancer Therapeutics Market Size by Type
6.2.1 North America Transitional Cell Cancer Therapeutics Market Size by Type (2016-2021)
6.2.2 North America Transitional Cell Cancer Therapeutics Market Size by Type (2022-2027)
6.2.3 North America Transitional Cell Cancer Therapeutics Market Size by Type (2016-2027)
6.3 North America Transitional Cell Cancer Therapeutics Market Size by Application
6.3.1 North America Transitional Cell Cancer Therapeutics Market Size by Application (2016-2021)
6.3.2 North America Transitional Cell Cancer Therapeutics Market Size by Application (2022-2027)
6.3.3 North America Transitional Cell Cancer Therapeutics Market Size by Application (2016-2027)
6.4 North America Transitional Cell Cancer Therapeutics Market Size by Country
6.4.1 North America Transitional Cell Cancer Therapeutics Market Size by Country (2016-2021)
6.4.2 North America Transitional Cell Cancer Therapeutics Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Transitional Cell Cancer Therapeutics Market Size (2016-2027)
7.2 Europe Transitional Cell Cancer Therapeutics Market Size by Type
7.2.1 Europe Transitional Cell Cancer Therapeutics Market Size by Type (2016-2021)
7.2.2 Europe Transitional Cell Cancer Therapeutics Market Size by Type (2022-2027)
7.2.3 Europe Transitional Cell Cancer Therapeutics Market Size by Type (2016-2027)
7.3 Europe Transitional Cell Cancer Therapeutics Market Size by Application
7.3.1 Europe Transitional Cell Cancer Therapeutics Market Size by Application (2016-2021)
7.3.2 Europe Transitional Cell Cancer Therapeutics Market Size by Application (2022-2027)
7.3.3 Europe Transitional Cell Cancer Therapeutics Market Size by Application (2016-2027)
7.4 Europe Transitional Cell Cancer Therapeutics Market Size by Country
7.4.1 Europe Transitional Cell Cancer Therapeutics Market Size by Country (2016-2021)
7.4.2 Europe Transitional Cell Cancer Therapeutics Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Transitional Cell Cancer Therapeutics Market Size (2016-2027)
8.2 Asia-Pacific Transitional Cell Cancer Therapeutics Market Size by Type
8.2.1 Asia-Pacific Transitional Cell Cancer Therapeutics Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Transitional Cell Cancer Therapeutics Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Transitional Cell Cancer Therapeutics Market Size by Type (2016-2027)
8.3 Asia-Pacific Transitional Cell Cancer Therapeutics Market Size by Application
8.3.1 Asia-Pacific Transitional Cell Cancer Therapeutics Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Transitional Cell Cancer Therapeutics Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Transitional Cell Cancer Therapeutics Market Size by Application (2016-2027)
8.4 Asia-Pacific Transitional Cell Cancer Therapeutics Market Size by Region
8.4.1 Asia-Pacific Transitional Cell Cancer Therapeutics Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Transitional Cell Cancer Therapeutics Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Transitional Cell Cancer Therapeutics Market Size (2016-2027)
9.2 Latin America Transitional Cell Cancer Therapeutics Market Size by Type
9.2.1 Latin America Transitional Cell Cancer Therapeutics Market Size by Type (2016-2021)
9.2.2 Latin America Transitional Cell Cancer Therapeutics Market Size by Type (2022-2027)
9.2.3 Latin America Transitional Cell Cancer Therapeutics Market Size by Type (2016-2027)
9.3 Latin America Transitional Cell Cancer Therapeutics Market Size by Application
9.3.1 Latin America Transitional Cell Cancer Therapeutics Market Size by Application (2016-2021)
9.3.2 Latin America Transitional Cell Cancer Therapeutics Market Size by Application (2022-2027)
9.3.3 Latin America Transitional Cell Cancer Therapeutics Market Size by Application (2016-2027)
9.4 Latin America Transitional Cell Cancer Therapeutics Market Size by Country
9.4.1 Latin America Transitional Cell Cancer Therapeutics Market Size by Country (2016-2021)
9.4.2 Latin America Transitional Cell Cancer Therapeutics Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Transitional Cell Cancer Therapeutics Market Size (2016-2027)
10.2 Middle East & Africa Transitional Cell Cancer Therapeutics Market Size by Type
10.2.1 Middle East & Africa Transitional Cell Cancer Therapeutics Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Transitional Cell Cancer Therapeutics Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Transitional Cell Cancer Therapeutics Market Size by Type (2016-2027)
10.3 Middle East & Africa Transitional Cell Cancer Therapeutics Market Size by Application
10.3.1 Middle East & Africa Transitional Cell Cancer Therapeutics Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Transitional Cell Cancer Therapeutics Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Transitional Cell Cancer Therapeutics Market Size by Application (2016-2027)
10.4 Middle East & Africa Transitional Cell Cancer Therapeutics Market Size by Country
10.4.1 Middle East & Africa Transitional Cell Cancer Therapeutics Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Transitional Cell Cancer Therapeutics Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 AstraZeneca
11.1.1 AstraZeneca Company Details
11.1.2 AstraZeneca Business Overview
11.1.3 AstraZeneca Transitional Cell Cancer Therapeutics Introduction
11.1.4 AstraZeneca Revenue in Transitional Cell Cancer Therapeutics Business (2016-2021)
11.1.5 AstraZeneca Recent Development
11.2 Roche
11.2.1 Roche Company Details
11.2.2 Roche Business Overview
11.2.3 Roche Transitional Cell Cancer Therapeutics Introduction
11.2.4 Roche Revenue in Transitional Cell Cancer Therapeutics Business (2016-2021)
11.2.5 Roche Recent Development
11.3 Bristol-Myers Squibb
11.3.1 Bristol-Myers Squibb Company Details
11.3.2 Bristol-Myers Squibb Business Overview
11.3.3 Bristol-Myers Squibb Transitional Cell Cancer Therapeutics Introduction
11.3.4 Bristol-Myers Squibb Revenue in Transitional Cell Cancer Therapeutics Business (2016-2021)
11.3.5 Bristol-Myers Squibb Recent Development
11.4 Pfizer
11.4.1 Pfizer Company Details
11.4.2 Pfizer Business Overview
11.4.3 Pfizer Transitional Cell Cancer Therapeutics Introduction
11.4.4 Pfizer Revenue in Transitional Cell Cancer Therapeutics Business (2016-2021)
11.4.5 Pfizer Recent Development
11.5 Exelixis
11.5.1 Exelixis Company Details
11.5.2 Exelixis Business Overview
11.5.3 Exelixis Transitional Cell Cancer Therapeutics Introduction
11.5.4 Exelixis Revenue in Transitional Cell Cancer Therapeutics Business (2016-2021)
11.5.5 Exelixis Recent Development
11.6 Eisai
11.6.1 Eisai Company Details
11.6.2 Eisai Business Overview
11.6.3 Eisai Transitional Cell Cancer Therapeutics Introduction
11.6.4 Eisai Revenue in Transitional Cell Cancer Therapeutics Business (2016-2021)
11.6.5 Eisai Recent Development
11.7 Merck
11.7.1 Merck Company Details
11.7.2 Merck Business Overview
11.7.3 Merck Transitional Cell Cancer Therapeutics Introduction
11.7.4 Merck Revenue in Transitional Cell Cancer Therapeutics Business (2016-2021)
11.7.5 Merck Recent Development
11.8 Eli Lilly
11.8.1 Eli Lilly Company Details
11.8.2 Eli Lilly Business Overview
11.8.3 Eli Lilly Transitional Cell Cancer Therapeutics Introduction
11.8.4 Eli Lilly Revenue in Transitional Cell Cancer Therapeutics Business (2016-2021)
11.8.5 Eli Lilly Recent Development
11.9 Celgene
11.9.1 Celgene Company Details
11.9.2 Celgene Business Overview
11.9.3 Celgene Transitional Cell Cancer Therapeutics Introduction
11.9.4 Celgene Revenue in Transitional Cell Cancer Therapeutics Business (2016-2021)
11.9.5 Celgene Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Transitional Cell Cancer Therapeutics Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Transurethral Resection Of Bladder Tumor
Table 3. Key Players of Cystectomy
Table 4. Key Players of Urinary Diversion
Table 5. Global Transitional Cell Cancer Therapeutics Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Transitional Cell Cancer Therapeutics Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Transitional Cell Cancer Therapeutics Market Size by Regions (2016-2021) & (US$ Million)
Table 8. Global Transitional Cell Cancer Therapeutics Market Share by Regions (2016-2021)
Table 9. Global Transitional Cell Cancer Therapeutics Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 10. Global Transitional Cell Cancer Therapeutics Market Share by Regions (2022-2027)
Table 11. Transitional Cell Cancer Therapeutics Market Trends
Table 12. Transitional Cell Cancer Therapeutics Market Drivers
Table 13. Transitional Cell Cancer Therapeutics Market Challenges
Table 14. Transitional Cell Cancer Therapeutics Market Restraints
Table 15. Global Transitional Cell Cancer Therapeutics Revenue by Players (2016-2021) & (US$ Million)
Table 16. Global Transitional Cell Cancer Therapeutics Market Share by Players (2016-2021)
Table 17. Global Top Transitional Cell Cancer Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Transitional Cell Cancer Therapeutics as of 2020)
Table 18. Ranking of Global Top Transitional Cell Cancer Therapeutics Companies by Revenue (US$ Million) in 2020
Table 19. Global 5 Largest Players Market Share by Transitional Cell Cancer Therapeutics Revenue (CR5 and HHI) & (2016-2021)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Transitional Cell Cancer Therapeutics Product Solution and Service
Table 22. Date of Enter into Transitional Cell Cancer Therapeutics Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Transitional Cell Cancer Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 25. Global Transitional Cell Cancer Therapeutics Revenue Market Share by Type (2016-2021)
Table 26. Global Transitional Cell Cancer Therapeutics Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 27. Global Transitional Cell Cancer Therapeutics Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 28. Global Transitional Cell Cancer Therapeutics Market Size Share by Application (2016-2021) & (US$ Million)
Table 29. Global Transitional Cell Cancer Therapeutics Revenue Market Share by Application (2016-2021)
Table 30. Global Transitional Cell Cancer Therapeutics Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 31. Global Transitional Cell Cancer Therapeutics Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 32. North America Transitional Cell Cancer Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 33. North America Transitional Cell Cancer Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 34. North America Transitional Cell Cancer Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 35. North America Transitional Cell Cancer Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 36. North America Transitional Cell Cancer Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 37. North America Transitional Cell Cancer Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 38. Europe Transitional Cell Cancer Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 39. Europe Transitional Cell Cancer Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 40. Europe Transitional Cell Cancer Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 41. Europe Transitional Cell Cancer Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 42. Europe Transitional Cell Cancer Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 43. Europe Transitional Cell Cancer Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 44. Asia-Pacific Transitional Cell Cancer Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 45. Asia-Pacific Transitional Cell Cancer Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Transitional Cell Cancer Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 47. Asia-Pacific Transitional Cell Cancer Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Transitional Cell Cancer Therapeutics Market Size by Region (2016-2021) & (US$ Million)
Table 49. Asia-Pacific Transitional Cell Cancer Therapeutics Market Size by Region (2022-2027) & (US$ Million)
Table 50. Latin America Transitional Cell Cancer Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 51. Latin America Transitional Cell Cancer Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 52. Latin America Transitional Cell Cancer Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 53. Latin America Transitional Cell Cancer Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 54. Latin America Transitional Cell Cancer Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 55. Latin America Transitional Cell Cancer Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 56. Middle East & Africa Transitional Cell Cancer Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 57. Middle East & Africa Transitional Cell Cancer Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Transitional Cell Cancer Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 59. Middle East & Africa Transitional Cell Cancer Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Transitional Cell Cancer Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 61. Middle East & Africa Transitional Cell Cancer Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 62. AstraZeneca Company Details
Table 63. AstraZeneca Business Overview
Table 64. AstraZeneca Transitional Cell Cancer Therapeutics Product
Table 65. AstraZeneca Revenue in Transitional Cell Cancer Therapeutics Business (2016-2021) & (US$ Million)
Table 66. AstraZeneca Recent Development
Table 67. Roche Company Details
Table 68. Roche Business Overview
Table 69. Roche Transitional Cell Cancer Therapeutics Product
Table 70. Roche Revenue in Transitional Cell Cancer Therapeutics Business (2016-2021) & (US$ Million)
Table 71. Roche Recent Development
Table 72. Bristol-Myers Squibb Company Details
Table 73. Bristol-Myers Squibb Business Overview
Table 74. Bristol-Myers Squibb Transitional Cell Cancer Therapeutics Product
Table 75. Bristol-Myers Squibb Revenue in Transitional Cell Cancer Therapeutics Business (2016-2021) & (US$ Million)
Table 76. Bristol-Myers Squibb Recent Development
Table 77. Pfizer Company Details
Table 78. Pfizer Business Overview
Table 79. Pfizer Transitional Cell Cancer Therapeutics Product
Table 80. Pfizer Revenue in Transitional Cell Cancer Therapeutics Business (2016-2021) & (US$ Million)
Table 81. Pfizer Recent Development
Table 82. Exelixis Company Details
Table 83. Exelixis Business Overview
Table 84. Exelixis Transitional Cell Cancer Therapeutics Product
Table 85. Exelixis Revenue in Transitional Cell Cancer Therapeutics Business (2016-2021) & (US$ Million)
Table 86. Exelixis Recent Development
Table 87. Eisai Company Details
Table 88. Eisai Business Overview
Table 89. Eisai Transitional Cell Cancer Therapeutics Product
Table 90. Eisai Revenue in Transitional Cell Cancer Therapeutics Business (2016-2021) & (US$ Million)
Table 91. Eisai Recent Development
Table 92. Merck Company Details
Table 93. Merck Business Overview
Table 94. Merck Transitional Cell Cancer Therapeutics Product
Table 95. Merck Revenue in Transitional Cell Cancer Therapeutics Business (2016-2021) & (US$ Million)
Table 96. Merck Recent Development
Table 97. Eli Lilly Company Details
Table 98. Eli Lilly Business Overview
Table 99. Eli Lilly Revenue in Transitional Cell Cancer Therapeutics Business (2016-2021) & (US$ Million)
Table 100. Eli Lilly Recent Development
Table 101. Celgene Company Details
Table 102. Celgene Business Overview
Table 103. Celgene Transitional Cell Cancer Therapeutics Product
Table 104. Celgene Revenue in Transitional Cell Cancer Therapeutics Business (2016-2021) & (US$ Million)
Table 105. Celgene Recent Development
Table 106. Research Programs/Design for This Report
Table 107. Key Data Information from Secondary Sources
Table 108. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Transitional Cell Cancer Therapeutics Market Share by Type: 2020 VS 2027
Figure 2. Transurethral Resection Of Bladder Tumor Features
Figure 3. Cystectomy Features
Figure 4. Urinary Diversion Features
Figure 5. Global Transitional Cell Cancer Therapeutics Market Share by Application: 2020 VS 2027
Figure 6. Hospital Case Studies
Figure 7. Cancer Research Institutes Case Studies
Figure 8. Multispecialty Clinics Case Studies
Figure 9. Ambulatory Surgical Centers Case Studies
Figure 10. Transitional Cell Cancer Therapeutics Report Years Considered
Figure 11. Global Transitional Cell Cancer Therapeutics Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 12. Global Transitional Cell Cancer Therapeutics Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 13. Global Transitional Cell Cancer Therapeutics Market Share by Regions: 2020 VS 2027
Figure 14. Global Transitional Cell Cancer Therapeutics Market Share by Regions (2022-2027)
Figure 15. Global Transitional Cell Cancer Therapeutics Market Share by Players in 2020
Figure 16. Global Top Transitional Cell Cancer Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Transitional Cell Cancer Therapeutics as of 2020
Figure 17. The Top 10 and 5 Players Market Share by Transitional Cell Cancer Therapeutics Revenue in 2020
Figure 18. Global Transitional Cell Cancer Therapeutics Revenue Market Share by Type (2016-2021)
Figure 19. Global Transitional Cell Cancer Therapeutics Revenue Market Share by Type (2022-2027)
Figure 20. North America Transitional Cell Cancer Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 21. North America Transitional Cell Cancer Therapeutics Market Share by Type (2016-2027)
Figure 22. North America Transitional Cell Cancer Therapeutics Market Share by Application (2016-2027)
Figure 23. North America Transitional Cell Cancer Therapeutics Market Share by Country (2016-2027)
Figure 24. United States Transitional Cell Cancer Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Canada Transitional Cell Cancer Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Transitional Cell Cancer Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Transitional Cell Cancer Therapeutics Market Share by Type (2016-2027)
Figure 28. Europe Transitional Cell Cancer Therapeutics Market Share by Application (2016-2027)
Figure 29. Europe Transitional Cell Cancer Therapeutics Market Share by Country (2016-2027)
Figure 30. Germany Transitional Cell Cancer Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. France Transitional Cell Cancer Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. U.K. Transitional Cell Cancer Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Italy Transitional Cell Cancer Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Russia Transitional Cell Cancer Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Nordic Transitional Cell Cancer Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Transitional Cell Cancer Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Transitional Cell Cancer Therapeutics Market Share by Type (2016-2027)
Figure 38. Asia-Pacific Transitional Cell Cancer Therapeutics Market Share by Application (2016-2027)
Figure 39. Asia-Pacific Transitional Cell Cancer Therapeutics Market Share by Region (2016-2027)
Figure 40. China Transitional Cell Cancer Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Japan Transitional Cell Cancer Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. South Korea Transitional Cell Cancer Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Southeast Asia Transitional Cell Cancer Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. India Transitional Cell Cancer Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Australia Transitional Cell Cancer Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Transitional Cell Cancer Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Transitional Cell Cancer Therapeutics Market Share by Type (2016-2027)
Figure 48. Latin America Transitional Cell Cancer Therapeutics Market Share by Application (2016-2027)
Figure 49. Latin America Transitional Cell Cancer Therapeutics Market Share by Country (2016-2027)
Figure 50. Mexico Transitional Cell Cancer Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Brazil Transitional Cell Cancer Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Transitional Cell Cancer Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Transitional Cell Cancer Therapeutics Market Share by Type (2016-2027)
Figure 54. Middle East & Africa Transitional Cell Cancer Therapeutics Market Share by Application (2016-2027)
Figure 55. Middle East & Africa Transitional Cell Cancer Therapeutics Market Share by Country (2016-2027)
Figure 56. Turkey Transitional Cell Cancer Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Saudi Arabia Transitional Cell Cancer Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. UAE Transitional Cell Cancer Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. AstraZeneca Revenue Growth Rate in Transitional Cell Cancer Therapeutics Business (2016-2021)
Figure 60. Roche Revenue Growth Rate in Transitional Cell Cancer Therapeutics Business (2016-2021)
Figure 61. Bristol-Myers Squibb Revenue Growth Rate in Transitional Cell Cancer Therapeutics Business (2016-2021)
Figure 62. Pfizer Revenue Growth Rate in Transitional Cell Cancer Therapeutics Business (2016-2021)
Figure 63. Exelixis Revenue Growth Rate in Transitional Cell Cancer Therapeutics Business (2016-2021)
Figure 64. Eisai Revenue Growth Rate in Transitional Cell Cancer Therapeutics Business (2016-2021)
Figure 65. Merck Revenue Growth Rate in Transitional Cell Cancer Therapeutics Business (2016-2021)
Figure 66. Eli Lilly Revenue Growth Rate in Transitional Cell Cancer Therapeutics Business (2016-2021)
Figure 67. Celgene Revenue Growth Rate in Transitional Cell Cancer Therapeutics Business (2016-2021)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed

---